BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all purchasers of the securities of OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ:OVAS) between February 25, 2013 and September 10, 2013, inclusive (the “Class Period”).
OvaScience is engaged in the discovery, development and commercialization of new treatments for infertility. The Company’s product AUGMENT is an assisted reproductive technology which complements the existing standard of practice for an in vitro fertilization cycle. The Complaint alleges that the Company misrepresented or failed to disclose material information concerning the clinical development of AUGMENT and regulatory concerns raised by the Food and Drug Administration that could potentially threaten or delay FDA approval of AUGMENT. On September 10, 2013, OvaScience disclosed that it was suspending enrollment of the AUGMENT clinical trial in the United States, after the Company received a letter from the FDA questioning whether AUGMENT qualified for reduced regulatory oversight and advising the Company to file an Investigational New Drug application.
If you are a member of the Class described above, you have until August 5, 2014, to move the Court to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to email@example.com, or visit our website at http://www.howardsmithlaw.com.